Open AccessFactors Influencing Response to Aflibercept in Diabetic Macular Oedema Patients in a Diverse North West London Population: A Real-World Study
Author(s) -
Sing Yue Sim,
Arevik Ghulakhszian,
Amal Minocha,
Dhannie Ramcharan,
Soroush Nokhostin,
Richard Cheong-Leen,
Sheena George,
Esther Posner,
Christiana Dinah
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s314614
Subject(s) - aflibercept , medicine , diabetic retinopathy , visual acuity , ophthalmology , retrospective cohort study , cohort , macular degeneration , ranibizumab , cohort study , optometry , surgery , bevacizumab , diabetes mellitus , chemotherapy , endocrinology
Diabetic macular oedema (DMO) is the leading cause of sight impairment in working age populations in developed countries. Current first line treatment for centre-involving DMO involves intravitreal anti-VEGF but treatment response can be variable. In this retrospective, real world, multi-centre cohort study, we aim to identify ocular and systemic characteristics that correlate with anatomical and functional outcomes for treatment-naive DMO patients treated with intravitreal aflibercept.